Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a clinical study titled ‘MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma.’ The study aims to determine the Recommended Phase 2 Dose and assess the clinical benefits of elranatamab, a BCMA-CD3 bispecific antibody, when combined with other anti-cancer therapies for patients with multiple myeloma. This research is significant as it explores new therapeutic combinations for a challenging cancer type.
The study tests two main interventions: Elranatamab combined with Nirogacestat, a gamma secretase inhibitor, and Elranatamab combined with lenalidomide and dexamethasone, both targeting multiple myeloma treatment.
This interventional study is designed as a non-randomized, parallel assignment with no masking, focusing primarily on treatment. It aims to explore the effectiveness of the drug combinations in treating multiple myeloma.
The study began on October 27, 2021, with its last update submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates or results.
The study’s outcome could significantly impact Pfizer’s stock performance and investor sentiment, as successful results may enhance the company’s oncology portfolio. Competitors in the oncology space will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.